Title:
MULTISPECIFIC ANTIBODIES AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/078450
Kind Code:
A1
Abstract:
Provided are multispecific antibodies (e.g., bispecific antibodies) or antigen-binding fragments thereof. In one aspect, the multispecific antibodies or antigen-binding fragments thereof can bind to a T cell antigen (e.g., CD3) and/or a tumor-associated antigen (e.g., CEACAM5), or a combination thereof.
More Like This:
Inventors:
ZHOU CHANGHUA (CN)
WANG LUQUAN (CN)
ZHANG JIANBING (CN)
WANG LUQUAN (CN)
ZHANG JIANBING (CN)
Application Number:
PCT/CN2022/130399
Publication Date:
May 11, 2023
Filing Date:
November 07, 2022
Export Citation:
Assignee:
VIBRANT PHARMA LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C12N15/13
Domestic Patent References:
| WO2020151762A1 | 2020-07-30 |
Foreign References:
| EP3733715A1 | 2020-11-04 | |||
| CN110357966A | 2019-10-22 | |||
| CN106188305A | 2016-12-07 | |||
| CN113474372A | 2021-10-01 |
Other References:
CHEN SIQI; LI JING; LI QING; WANG ZHONG: "Bispecific antibodies in cancer immunotherapy.", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 12, no. 0, 1 June 2016 (2016-06-01), US , pages 2491 - 2500, XP009193384, ISSN: 2164-554X, DOI: 10.1080/21645515.2016.1187802
LI LI, HE PING, ZHOU CHANGHUA, JING LI, DONG BIN, CHEN SIQI, ZHANG NING, LIU YAWEI, MIAO JI, WANG ZHONG, LI QING: "A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing", JOURNAL OF IMMUNOTHERAPY, vol. 38, no. 9, 1 November 2015 (2015-11-01), US , pages 350 - 356, XP055319111, ISSN: 1524-9557, DOI: 10.1097/CJI.0000000000000099
LUTTERBUESE， R. ET AL: "Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA", JOURNAL OF IMMUNOTHERAPY, vol. 32, no. 4, 31 May 2009 (2009-05-31), pages 341 - 352, XP009149772
NIE， S.W. ET AL: "Biology drives the discovery of bispecific antibodies as innovative therapeutics", ANTIBODY THERAPEUTICS, vol. 3, no. 1, 17 February 2020 (2020-02-17), pages 18 - 62, XP055776258, DOI: 10.1093/abt/tbaa003
LI LI, HE PING, ZHOU CHANGHUA, JING LI, DONG BIN, CHEN SIQI, ZHANG NING, LIU YAWEI, MIAO JI, WANG ZHONG, LI QING: "A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing", JOURNAL OF IMMUNOTHERAPY, vol. 38, no. 9, 1 November 2015 (2015-11-01), US , pages 350 - 356, XP055319111, ISSN: 1524-9557, DOI: 10.1097/CJI.0000000000000099
LUTTERBUESE， R. ET AL: "Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA", JOURNAL OF IMMUNOTHERAPY, vol. 32, no. 4, 31 May 2009 (2009-05-31), pages 341 - 352, XP009149772
NIE， S.W. ET AL: "Biology drives the discovery of bispecific antibodies as innovative therapeutics", ANTIBODY THERAPEUTICS, vol. 3, no. 1, 17 February 2020 (2020-02-17), pages 18 - 62, XP055776258, DOI: 10.1093/abt/tbaa003
Attorney, Agent or Firm:
MERITS IP LTD. (CN)
Download PDF:
Previous Patent: METHOD, APPARATUS, AND MEDIUM FOR VIDEO PROCESSING
Next Patent: COMPOUND USED AS CDK7 KINASE INHIBITOR AND USE THEREOF
Next Patent: COMPOUND USED AS CDK7 KINASE INHIBITOR AND USE THEREOF